SMYD3 and non-small cell lung carcinoma: Additionally, a recent study conducted by Zhang et al. showed that SMYD3 expression levels were higher in NSCLC KRAS-mutated patient-derived xenografts that responded to combination treatment with a MEK + BCL-X/BCL-2 inhibitor (inhibitor that induces apoptosis) compared to treatment-resistant tumors [71].